Clinical Trials Browser

Active not recruiting × Adenoma, Islet Cell × Clear all

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Active not recruiting

144 enrolled 15 charts

Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Phase 2 Active not recruiting

20 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT06406387 2026-01-13

FORESEE

Active not recruiting

100 enrolled

Adenoma, Islet Cell

NCT06148636 2025-11-04

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Phase EARLY_PHASE1 Active not recruiting

24 enrolled

EndocrineNET

Adenoma, Islet Cell, Recurrence, Neuroendocrine Tumors

NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Active not recruiting

31 enrolled

Adenoma, Islet Cell

NCT03022188 2024-02-21

Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

Active not recruiting

100 enrolled

EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03043508 2019-05-23

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)

Active not recruiting

45 enrolled

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive

Clinical Trials

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

FORESEE

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)